Vertex calls for changes to NICE as CF drug profits soarVertex has revealed financial figures that are likely to go down well with investors, but not patients in Share XVertex calls for changes to NICE as CF drug profits soarhttps://pharmaphorum.com/news/vertex-calls-for-changes-to-nice-as-cf-drug-profits-soar/
Campaigners urge NHS to ignore patents on Vertex’s CF drugThe fight to get Vertex’s cystic fibrosis drug Orkambi available on England’s NHS continues, after pressure groups called Share XCampaigners urge NHS to ignore patents on Vertex’s CF drughttps://pharmaphorum.com/news/campaigners-urge-nhs-to-ignore-patents-on-vertexs-cf-drug/
Cystic fibrosis patients lobby Vertex to drop drug pricesHealthcare professionals and patient groups have written to Vertex’s CEO Jeffrey Leiden in a bid to resolve a Share XCystic fibrosis patients lobby Vertex to drop drug priceshttps://pharmaphorum.com/news/cystic-fibrosis-patients-lobby-vertex-to-drop-drug-prices/
Vertex licenses back CRISPR compounds from German MerckUS pharma Vertex has licensed back two gene editing compounds that can be used with CRISPR/Cas9 technology, from Share XVertex licenses back CRISPR compounds from German Merckhttps://pharmaphorum.com/news/vertex-licenses-back-crispr-compounds-from-german-merck/
Vertex sacks top exec, citing ‘personal behaviour’Vertex has fired its chief operating officer and acting chief financial officer, Ian Smith, citing unspecified “personal behaviour” Share XVertex sacks top exec, citing ‘personal behaviour’https://pharmaphorum.com/news/vertex-sacks-top-exec-citing-personal-behaviour/
Vertex’s CF drug gets label extension as pricing row continuesWhile UK cystic fibrosis patients continue their long wait for access to Vertex’s Orkambi, the drug has received Share XVertex’s CF drug gets label extension as pricing row continueshttps://pharmaphorum.com/news/vertexs-cf-drug-gets-label-extension-as-pricing-row-continues/
Scotland’s NHS could reimburse Vertex CF drugs, price row ongoing in EnglandVertex is to file its two latest cystic fibrosis drugs with Scotland’s drug cost watchdog in a bid Share XScotland’s NHS could reimburse Vertex CF drugs, price row ongoing in Englandhttps://pharmaphorum.com/news/vertex-smc-nice-orkambi-symkevi/
Vertex told to reveal CF drug price, as MPs begin inquiryUK politicians could go public with the price of Vertex’s cystic fibrosis drug Orkambi, if the company does Share XVertex told to reveal CF drug price, as MPs begin inquiryhttps://pharmaphorum.com/news/vertex-told-to-reveal-cf-drug-price-as-mps-begin/
Vertex wins European approval for new cystic fibrosis combinationEuropean regulators have approved Vertex’s new cystic fibrosis (CF) combination treatment Symkevi. The European Commission’s greenlight for Symkevi Share XVertex wins European approval for new cystic fibrosis combinationhttps://pharmaphorum.com/news/vertex-european-approval-cystic-fibrosis/
